Skip to main content

Day: July 28, 2020

Gran Tierra Announces Release Date for its 2020 Second Quarter Results, Conference Call and Webcast Details

CALGARY, Alberta, July 28, 2020 (GLOBE NEWSWIRE) — Gran Tierra Energy Inc. (“Gran Tierra”) (NYSE American:GTE) (TSX:GTE) (LSE:GTE), announces that the Company will release its 2020 second quarter financial and operating results on Tuesday, August 4, 2020, after market close. A conference call to discuss the 2020 second quarter results will be held at 11:00 a.m. Eastern Time (9:00 a.m. Mountain Time) the following day, Wednesday August 5, 2020. Details of the conference call are as follows:Interested parties may also access the live webcast on the investor relations page of Gran Tierra’s website at www.grantierra.com. An archive of the webcast will be available on Gran Tierra’s website until August 12, 2020. In addition, an audio replay of the conference call will be available following the call until August 12, 2020.  To access...

Continue reading

Grupo TMM Reports 2020 Second-Quarter Financial Results

(In Millions of Mexican Pesos)2020 Second-Quarter Financial Results Include:Consolidated Accumulated Income of $635.3 million.Free Cash Flow of $324.3 million.No Net Debt; Total Debt is lower than Free Cash Flow.Stockholders’ Equity of $2,388.5 million.Financial Debt of 10.4 percent from Stockholders’ Equity.MEXICO CITY, July 28, 2020 (GLOBE NEWSWIRE) — Grupo TMM, S.A.B. (OTC: GTMAY and BMV: TMM A; “TMM” or the “Company”), a Mexican Maritime-management transportation and logistics Company, reported today its financial results for the second quarter.MANAGEMENT OVERVIEWJosé F. Serrano, Chairman and Chief Executive Officer of Grupo TMM, said, “The prolonged suspension of operations in the public, private and social sectors due to the COVID-19 pandemic, as well as the delayed recovery from the economic slowdown and the drop in global...

Continue reading

Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease

SEATTLE, July 28, 2020 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced today the launch of ImmuneSense Lyme™, a research study to inform the development of an improved test to detect Lyme disease in the early stages of an infection, when the disease is most treatable but often missed or misdiagnosed. The study calls for approximately 1,000 participants in the Northeast, mid-Atlantic and upper Midwest, where 96% of Lyme cases occur. Participants can be evaluated at a local study site in their area or soon via tele-health in the comfort and safety of their own homes. “Lyme disease can be impossible to treat, particularly if it is not diagnosed early, and the symptoms of late stage Lyme disease can be so severe that it causes people to lose their jobs and have trouble caring for their families,” said Linda...

Continue reading

First Commonwealth Announces Second Quarter 2020 Earnings; Declares Quarterly Dividend

INDIANA, Pa., July 28, 2020 (GLOBE NEWSWIRE) — First Commonwealth Financial Corporation (NYSE: FCF) today announced financial results for the second quarter of 2020.Financial Summary(1)  Core operating results are a non-GAAP measure used by management to measure performance in operating the business that management believes enhances investors’ ability to better understand the underlying business performance and trends related to core business activities. A full reconciliation of non-GAAP financial measures can be found at the end of the financial statements which accompany this release.(2)  Reserve build represents the amount by which the provision for credit losses exceeds net charge-offs, while reserve release represents the amount by which net charge-offs exceed the provision for credit losses.      Second Quarter 2020...

Continue reading

Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia

AL001 was generally safe and well-tolerated in Phase 1b study and after continuous dosing in 15 asymptomatic and symptomatic FTD-GRN participants in Phase 2 studyTreatment with AL001 in Phase 2 study resulted in sustained restoration of plasma progranulin levels in all FTD-GRN participants back to normal range and the majority of symptomatic FTD-GRN participants showed a decrease in plasma neurofilament light chain (NfL) levels from baseline Pivotal Phase 3 study initiated in July 2020SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced preliminary data from its Phase 1b and open-label Phase 2 studies of AL001, for the treatment of people with frontotemporal dementia with a progranulin gene (GRN) mutation (FTD-GRN)....

Continue reading

Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption

CALGARY, Alberta, July 28, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announces that it intends to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of certain continuous disclosure documents for a period of up to 45 days.The Company intends to rely on the exemptive relief to extend the date of filing of its annual financial statements for the year ended April 30, 2020 and related management’s discussion and analysis pursuant to National Instrument 51-102 (collectively, the “Annual Filings”).Resverlogix expects to rely on the exemption to file the Annual Filings on or before September 11, 2020, and notes that management and other insiders are subject...

Continue reading

Timberland Bancorp Announces Third Fiscal Quarter Earnings

Net Income of $6.21 Million and EPS of $0.74PPP Loan Originations of $123 millionReturn on Average Assets of 1.70%Return on Average Equity of 13.83%Announces $0.20 Quarterly Cash DividendHOQUIAM, Wash., July 28, 2020 (GLOBE NEWSWIRE) — Timberland Bancorp, Inc. (NASDAQ: TSBK) (“Timberland” or “the Company”) today reported net income of $6.21 million for the quarter ended June 30, 2020 compared to $5.05 million for the preceding quarter and $5.96 million for the comparable quarter one year ago.  Earnings per diluted common share (“EPS”) were $0.74 for the current quarter compared to $0.60 for the preceding quarter and $0.70 for the comparable quarter one year ago.  Net income for the quarters ended June 30, 2020 and March 31, 2020 was reduced by provisions to the loan loss reserve of $1.00 million and $2.00 million, respectively,...

Continue reading

Toromont Announces Results for the Second Quarter of 2020 and Quarterly Dividend

TORONTO, July 28, 2020 (GLOBE NEWSWIRE) — Toromont Industries Ltd. (TSX: TIH) reported financial results for the second quarter ended June 30, 2020.“From the start of the COVID-19 pandemic, Toromont has continued to focus efforts on three areas: safeguarding our employees, servicing our customers’ needs and protecting our business for the future,” said Scott J. Medhurst, President and Chief Executive Officer of Toromont Industries Ltd. “As a result of reduced economic activity, caused by the response to the COVID-19 pandemic, we experienced lower earnings and net income in the quarter. Revenue decline lessened as the quarter progressed while remaining below prior year levels. We appreciate our entire team’s effort and commitment to supporting our customers during this challenging time.”Highlights:Consolidated resultsRevenues decreased...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.